FibroGen (FGEN) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
FibroGen (FGEN) PT Lowered to $79 at Stifel
February 28, 2018 6:27 AM ESTStifel lowered its price target on FibroGen (NASDAQ: FGEN) to $79.00 (from $80.00) while maintaining a Buy rating following Q4 results.
Analyst Alex Schwartz noted for chronic kidney disease (CKD) anemia with roxadustat, the company now guided topline data in the U.S. during 4Q18 and an NDA filing in 1H19.
... More